1. Home
  2. ENLV vs ARMP Comparison

ENLV vs ARMP Comparison

Compare ENLV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$4.20

Market Cap

149.0M

Sector

Health Care

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$4.71

Market Cap

156.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENLV
ARMP
Founded
2005
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.0M
156.4M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
ENLV
ARMP
Price
$4.20
$4.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$20.00
$15.00
AVG Volume (30 Days)
280.7K
263.2K
Earning Date
05-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$2.35
52 Week High
$7.64
$14.98

Technical Indicators

Market Signals
Indicator
ENLV
ARMP
Relative Strength Index (RSI) 57.84 39.57
Support Level $0.79 $3.48
Resistance Level $7.64 $7.67
Average True Range (ATR) 0.59 0.52
MACD -0.09 0.16
Stochastic Oscillator 50.64 55.33

Price Performance

Historical Comparison
ENLV
ARMP

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: